Search results for "ascites"

showing 10 items of 94 documents

Treatment of Malignant Ascites with a Second Cycle of Catumaxomab in Gastric Signet Cell Carcinoma - a Report of 2 Cases

2014

<b><i>Summary</i></b><b><i>Background: </i></b>Malignant ascites is a frequent complication in gastrointestinal malignancy and is unresponsive to systemic therapies. Therapeutic options are limited, and repeated paracentesis is associated with increased loss of fluids and proteins, and impaired quality of life. The bi-specific trifunctional antibody catumaxomab has been approved for the treatment of refractory ascites. It has been proposed that repeated application leads to formation of human anti-mouse antibodies with a decrease in effectiveness and potentially hypersensitivity reactions. <b><i>Case Report: </i></b>Her…

MaleCancer Researchmedicine.medical_specialtyCatumaxomabGastroenterologyStomach NeoplasmsInternal medicineAntibodies BispecificAscitesmedicineParacentesisCarcinomaHumansInfusions ParenteralPeritoneal Neoplasmsmedicine.diagnostic_testSignet ring cellbusiness.industryAscitesCancerHematologyMiddle Agedmedicine.diseaseTrifunctional antibodySurgeryOncologyRetreatmentFemalemedicine.symptomComplicationbusinessCarcinoma Signet Ring Cellmedicine.drugOncology Research and Treatment
researchProduct

Clinicopathological profile of gastrointestinal tuberculosis: a multinational ID-IRI study

2020

Data are relatively scarce on gastro-intestinal tuberculosis (GITB). Most studies are old and from single centers, or did not include immunosuppressed patients. Thus, we aimed to determine the clinical, radiological, and laboratory profiles of GITB. We included adults with proven GITB treated between 2000 and 2018. Patients were enrolled from 21 referral centers in 8 countries (Belgium, Egypt, France, Italy, Kazakhstan, Saudi Arabia, UK, and Turkey). One hundred four patients were included. Terminal ileum (n = 46, 44.2%), small intestines except terminal ileum (n = 36, 34.6%), colon (n = 29, 27.8%), stomach (n = 6, 5.7%), and perianal (one patient) were the sites of GITB. One-third of all p…

MaleCirrhosismedicine.medical_treatmentretrospective studylaparoscopyColonoscopymultimodal imagingComorbidityGastroenterologyprotionamide0302 clinical medicineLaparotomyAscitesamikacinMedicinebedaquilinePathologie maladies infectieusesintestine biopsyadultsteroidclinical trialGeneral MedicinerifabutinMicrobiologie et protistologie [entomologiephytoparasitolog.]priority journaldiabetes mellitushistopathologybiological productMicrobiology (medical)Microbiologie et protistologie [parasitologie hum. et anim.]medicine.medical_specialtyTuberculosis030106 microbiologymalignant neoplasmArticle03 medical and health scienceslaparotomyHuman immunodeficiency virus infectionmolecular diagnosisHumansTuberculosisGastro-intestinalhumanRetrospective Studiescolondisease predispositionmicrobiologyTuberculosis; Immune-suppression; Gastro-intestinal; Endoscopy;anusmedicine.diseasemajor clinical studymulticenter studyaminosalicylic acidcyclophosphamide0301 basic medicineBiopsyAntitubercular Agentsethambutolrifampicinterminal ileumcolonoscopyofloxacin030212 general & internal medicineLaparoscopyazathioprinemedicine.diagnostic_testIncidence (epidemiology)gastrointestinal tuberculosisDisease Managementchronic kidney failurecycloserineInfectious DiseasesfemaleTreatment OutcomeMolecular Diagnostic Techniquesdiagnostic testDisease Susceptibilitymedicine.symptommoxifloxacinSymptom AssessmentImmune-suppressionstomachisoniazidpyrazinamidestreptomycinliver cirrhosispatient referrallinezolidInternal medicineBiopsybusiness.industryEndoscopyMycobacterium tuberculosishuman tissueclinical featureTreatmentTuberculosis Gastrointestinaltuberculostatic agentbusinessMicrobiologie et protistologie [bacteriol.virolog.mycolog.]
researchProduct

Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting

2018

International audience; BACKGROUNDS & AIMS: Treating patients with decompensated cirrhosis with direct-acting antiviral (DAA) therapy while on the waiting list for liver transplantation results in substantial improvement of liver function allowing 1 in 4 patients to be removed from the waiting list or delisted, as reported in a previous study promoted by the European Liver and Intestine Transplant Association (ELITA). The aim of this study was to report on clinical outcomes of delisted patients, including mortality risk, hepatocellular carcinoma development and clinical decompensation requiring relisting. METHODS: One hundred and forty-two HCV-positive patients on the liver transplant waiti…

MaleLiver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma HepatocellularWaiting Listsmedicine.medical_treatment[SDV]Life Sciences [q-bio]Liver transplantationSeverity of Illness IndexAntiviral Agents03 medical and health sciences0302 clinical medicineInternal medicineAscitesmedicineHumansDecompensationChronicdirect-acting antiviralsdirect-acting antiviralHepatologyliver transplantationbusiness.industrydelistingcirrhosisCarcinomaLiver NeoplasmsHepatocellularHepatitis CTransplant Waiting ListHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis C3. Good healthItaly030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleLiver functionmedicine.symptombusinesscirrhosi
researchProduct

Diffuse malignant biphasic peritoneal mesothelioma with cystic areas

2016

We report a case of peritoneal biphasic mesothelioma with cystic areas in a patient with professional exposure to asbestos. It showed focal epithelial glandular and papillary proliferations, also presenting fluid filled cysts, whose wall consisted of a proliferation of spindle cells. Atypia and mitoses were very scanty. EMA, vimentin, CK5/6, D2-40, calretinin and P53 were positive and desmin was negative in both epithelial and spindle areas, including the ones surrounding the cystic spaces. These findings gave an essential aid in the differential diagnosis with a benign cystic mesothelioma and with a cystic epithelial mesothelioma with secondary pseudosarcomatous myofibroblastic proliferati…

MaleMesotheliomaLung NeoplasmsMesothelioma MalignantAscitesAsbestosMesothelioma CysticPemetrexedSettore MED/08 - Anatomia PatologicaAppendicitisCystic Mesothelioma Immunohistochemistry Malignant Mesothelioma Peritoneal Diseases Mesothelial Neoplasms.Diagnosis DifferentialSettore MED/18 - Chirurgia GeneraleCrohn DiseaseOccupational ExposureAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorHumansCisplatinDiagnostic ErrorsPeritoneal NeoplasmsAged
researchProduct

Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study.

2013

Background Current recommendations for empirical antimicrobial therapy in spontaneous bacterial peritonitis (SBP) are based on quite old trials. Since microbial epidemiology and the management of patients have changed, whether these recommendations are still appropriate must be confirmed. Methods An observational study that exhaustively collected the clinical and biological data associated with positive ascitic fluid cultures was conducted in four French university hospitals in 2010–2011. Results Two hundred and sixty-eight documented positive cultures were observed in 190 cirrhotic patients (median age 61.5 years, 58.5% Child score C). Of these, 57 were classified as confirmed SBP and 140 …

MalePathologymedicine.medical_specialtyAntibiotic susceptibilitymedicine.drug_classEpidemiologyAntibioticsCephalosporinResistanceContext (language use)Microbial Sensitivity TestsPeritonitisAmoxicillin-Potassium Clavulanate CombinationAntibiotic resistanceMedical microbiologySpontaneous bacterial peritonitisAnti-Infective Agents[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyEpidemiologyDrug Resistance BacterialmedicineEscherichia coliSpontaneous bacterial peritonitisAscitic FluidHumans[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyAgedCross Infection[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybusiness.industryBacterial InfectionsMiddle AgedAntimicrobialmedicine.disease3. Good healthAnti-Bacterial AgentsTreatment Outcome[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesBacterascitesFemalebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyResearch Article
researchProduct

Lysosomal storage disorder in non-immunological hydrops fetalis (NIHF) - more common than assumed? Report of four cases with transient NIHF and a rev…

2012

Abstract Background Lysosomal storage disorders (LSD) are a rare cause of non immunological hydrops fetalis (NIHF) and congenital ascites. The reported incidence is about 1%. The incidence of idiopathic NIHF is estimated to be about 18%. Patients and methods We report four cases with transient hydrops fetalis resulting from LSD and performed a literature review on LSD with NIHF and congenital ascites in combination. Results At present, 12 different LSDs are described to be associated with NIHF or congenital ascites. Most patients had a family history of NIHF, where the preceding sibling had not been examined. A diagnostic approach to the fetus with NIHF due to suspected LSD either in utero …

MalePathologymedicine.medical_specialtyHydrops FetalisNon-immunological hydrops fetalisPharmacology toxicologylcsh:MedicineLysosomal storage diseaseLysosomal storage disordersClinical approachPregnancyHydrops fetalisAscitesLysosomal storage diseaseHumansMedicineGenetics(clinical)Pharmacology (medical)Genetics (clinical)Medicine(all)business.industryResearchIncidence (epidemiology)lcsh:RTransient hydropsGeneral Medicinemedicine.diseaseCongenital ascitesLysosomal Storage DiseasesImmunologyFemalemedicine.symptombusinessOrphanet Journal of Rare Diseases
researchProduct

Pancreatic ascites hemoglobin contributes to the systemic response in acute pancreatitis.

2015

Upon hemolysis extracellular hemoglobin causes oxidative stress and cytotoxicity due to its peroxidase activity. Extracellular hemoglobin may release free hemin, which increases vascular permeability, leukocyte recruitment, and adhesion molecule expression. Pancreatitis-associated ascitic fluid is reddish and may contain extracellular hemoglobin. Our aim has been to determine the role of extracellular hemoglobin in the local and systemic inflammatory response during severe acute pancreatitis in rats. To this end we studied taurocholate-induced necrotizing pancreatitis in rats. First, extracellular hemoglobin in ascites and plasma was quantified and the hemolytic action of ascitic fluid was …

MaleTaurocholic AcidVascular Endothelial Growth Factor Amedicine.medical_specialtyNecrosisInterleukin-1betaAbdominal FatAdipose tissueVascular permeabilityInflammationBiochemistryHemoglobinsNecrosisPhysiology (medical)Internal medicinemedicineExtracellularAnimalsAscitic FluidPeritoneal LavageRats WistarPancreasPeroxidasebusiness.industryPancreatitis Acute NecrotizingTumor Necrosis Factor-alphaAscitesmedicine.diseaseHypoxia-Inducible Factor 1 alpha SubunitInterleukin-10RatsOxidative StressEndocrinologyGene Expression RegulationImmunologyPancreatitisAcute pancreatitisHemoglobinmedicine.symptombusinessFree radical biologymedicine
researchProduct

Accumulation of hydroxyethyl starch (HES) in the liver of patients with renal failure and portal hypertension

1986

Summary Hydroxyethyl starch (HES) has gained wide clinical acceptance as a colloidal plasma substitute. We were able to study the liver biopsies of two patients with renal failure who developed ascites after repeated infusions of HES. All types of liver cells displayed massive accumulation of HES with the morphologic resemblance to a storage disease. These changes could be distinguished clearly from the lesions of a hereditary disorder by light and electron microscopy. Although it is difficult to establish a causative role for HES in the development of ascites on the bases of morphological changes alone, one should be cautious about giving HES to patients with renal failure until exact data…

Malemedicine.medical_specialtyResuscitationPathologyHydroxyethyl starchHydroxyethyl Starch DerivativesRenal DialysisHypertension PortalAscitesmedicineHumansreproductive and urinary physiologyHepatologybusiness.industryStarchMiddle Agedmedicine.diseaseSurgeryMicroscopy ElectronLiverKidney Failure ChronicPortal hypertensionFemaleHypotensionbiological phenomena cell phenomena and immunitymedicine.symptombusinessPerfusionmedicine.drugJournal of Hepatology
researchProduct

Metabolism of reduced pyridine nucleotides in ascites cell nuclei

1964

1. The conditions are described under which the fluorescence due to reduced pyridine nucleotides can be studied separately at nuclear and cytoplasmic sites of glass-grown ascites cells, by the use of a flow chamber in the microfluorimeter ofChance andLegallais.

NiacinamideHistologyNiacinFluorescenceFluorescence spectroscopyTissue Culture Techniqueschemistry.chemical_compoundPyridinemedicineFluorometryMicroscopy InterferenceNucleotideCitratesMolecular BiologyCell NucleusPharmacologychemistry.chemical_classificationMicroscopyNicotinamideHistocytochemistryNucleotidesResearchAscitesSuccinatesCell BiologyMetabolismNADMedical Laboratory TechnologyCell nucleusGlucoseMetabolismmedicine.anatomical_structureBiochemistrychemistryCytoplasmAmobarbitalNAD+ kinaseNADPHistochemie
researchProduct

Quality of life in patients with malignant ascites during catumaxomab treatment: Results from the CASIMAS trial.

2012

e13095^ Background: Malignant Ascites (MA) is associated with a poor prognosis and limited palliative treatment options. To demonstrate the value of a new treatment the assessment of quality of life (QoL) is of particular importance. Following the demonstration of catumaxomab’s potential to stabilize QoL and prolong the time to first deterioration of QoL, results from CASIMAS give evidence that the QoL of patients remains unaffected during catumaxomab treatment Methods: In a two-arm, open-label, multicentre phase II/III study 219 patients were randomized to catumaxomab plus premedication of 25 mg prednisolone (111 pts) or to catumaxomab alone (108 pts) QoL was measured using the EQ-5D visu…

OncologyCancer Researchmedicine.medical_specialtyPoor prognosisPalliative treatmentbusiness.industryCatumaxomabTreatment resultsSurgeryOncologyQuality of lifeInternal medicineAscitesMedicineIn patientmedicine.symptombusinessmedicine.drugJournal of Clinical Oncology
researchProduct